Reaction
Intestinal Dilatation reporting signals
As of the last recalculation, Intestinal Dilatation appears in 1,307 FAERS reports alongside 27 co-occurring drug terms. The strongest observed disproportionality signal is TEDUGLUTIDE (PRR 25.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Teduglutide | 21 | 25.2 | 25.2 |
| Phytonadione | 12 | 22.7 | 22.8 |
| Adalimumab-Fkjp | 50 | 17.8 | 17.9 |
| Adalimumab-Aaty | 49 | 17.1 | 17.1 |
| Mercaptopurine | 18 | 16.7 | 16.8 |
| Diphenoxylate Hydrochloride And Atropine Sulfate | 14 | 16.4 | 16.5 |
| Adalimumab-Adaz | 49 | 15.3 | 15.3 |
| Lactulose | 35 | 14.9 | 14.9 |
| Canakinumab | 10 | 14.8 | 14.8 |
| Valproate Sodium | 17 | 13.3 | 13.3 |
| Basiliximab | 9 | 12.3 | 12.3 |
| Haloperidol | 18 | 12.0 | 12.0 |
| Clozapine | 88 | 11.9 | 11.9 |
| Haloperidol Lactate | 18 | 11.7 | 11.7 |
| Piperacillin And Tazobactam | 9 | 11.3 | 11.3 |
| Infliximab-Dyyb | 20 | 11.1 | 11.1 |
| Leucovorin Calcium | 13 | 10.9 | 10.9 |
| Granisetron Hydrochloride | 7 | 10.7 | 10.7 |
| Granisetron | 7 | 10.7 | 10.7 |
| Vedolizumab | 53 | 10.2 | 10.2 |
| Sevoflurane | 5 | 9.6 | 9.6 |
| Vincristine Sulfate | 14 | 7.7 | 7.7 |
| Pegaspargase | 5 | 6.5 | 6.5 |
| Risankizumab-Rzaa | 32 | 6.4 | 6.4 |
| Irinotecan Hydrochloride | 5 | 6.2 | 6.2 |
| Oxaliplatin | 27 | 5.9 | 5.9 |
| Ustekinumab | 35 | 5.6 | 5.6 |